{
    "nctId": "NCT01373684",
    "officialTitle": "Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS)",
    "inclusionCriteria": "* Chronic hepatitis B (HBsAg positive \\> 6 months)\n* HBeAg negative within six months prior to initiation of peginterferon alfa-2a\n* HBV DNA \\< 200 IU/ml during nucleos(t)ide analogue (except Telbivudine) treatment within one month prior to initiation of peginterferon alfa-2a\n* Compensated liver disease\n* Age \\> 18 years\n* Written informed consent\n* Must have minimum age of 18 Years",
    "exclusionCriteria": "* Treatment with any investigational drug within 30 days of entry to this protocol\n* Current treatment with Telbivudine\n* Severe hepatitis activity as documented by ALT\\>10 x ULN\n* History of decompensated cirrhosis (defined as jaundice in the presence of cirrhosis, ascites, bleeding gastric or esophageal varices or encephalopathy)\n* Pre-existent neutropenia (neutrophils \\<1,500/mm3) or thrombocytopenia (platelets \\< 90,000/mm3)\n* Co-infection with hepatitis C virus, hepatitis D virus or human immunodeficiency virus (HIV)\n* Other acquired or inherited causes of liver disease: alcoholic liver disease, obesity induced liver disease, drug related liver disease, auto-immune hepatitis, hemochromatosis, Wilson's disease or alpha-1 antitrypsin deficiency\n* Alpha fetoprotein \\> 50 ng/ml\n* Hyper- or hypothyroidism (subjects requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met)\n* Immune suppressive treatment within the previous 6 months\n* Contra-indications for alfa-interferon therapy like suspected hypersensitivity to interferon or Peginterferon or any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study.\n* Pregnancy, breast-feeding\n* Other significant medical illness that might interfere with this study: significant pulmonary dysfunction in the previous 6 months, malignancy other than skin basocellular carcinoma in previous 5 years, immunodeficiency syndromes (e.g. HIV positivity, auto-immune diseases, organ transplants other than cornea and hair transplant)\n* Any medical condition requiring, or likely to require chronic systemic administration of steroids, during the course of the study\n* Substance abuse, such as alcohol (\\>80 g/day), I.V. drugs and inhaled drugs in the past 2 years.\n* Any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the study"
}